缩宫素增强与非镇静高强度聚焦超声治疗子宫肌瘤较单纯HIFU或子宫动脉栓塞显示出良好前景
研究比较了9例连续患者接受改良能量传输方案联合缩宫素增强的HIFU(研究组)与51例随机接受HIFU(24例)或子宫动脉栓塞(27例)的对照组。研究组无严重不良事件,3个月时肌瘤体积中位比例为51.1%,显著小于HIFU组的76.6%和UAE组的66.2%;6个月时研究组全部9例症状消失,生活质量良好比例显著更高,24个月内无需再干预。作者认为该治疗可能优于UAE,但需更大规模随机对照试验进一步评估。
要点
- 研究组3个月肌瘤体积中位比例为51.1%,显著小于HIFU组76.6%和UAE组66.2%。
- 研究组6个月全部9例症状消失,显著优于两个对照组。
- 研究组生活质量良好比例为5/7(71.4%),显著高于HIFU组3/24(12.5%)和UAE组7/27(25.9%)。
核心结论
- 改良能量传输方案联合缩宫素增强的HIFU治疗子宫肌瘤无严重不良事件,3个月和6个月影像与临床结果良好,24个月内无需再干预,可能优于UAE,但需更大规模随机对照试验进一步评估。
研究设计与样本
- 研究组为9例连续患者接受缩宫素增强与非镇静HIFU治疗;对照组为51例随机(1:1)接受HIFU(n=24)或子宫动脉栓塞(n=27)的患者。
关键影像表现/征象
- 3个月时研究组肌瘤体积中位比例为51.1%,HIFU组为76.6%,UAE组为66.2%。
- 6个月时研究组9/9(100%)患者症状消失。
- 研究组生活质量良好比例为5/7(71.4%),HIFU组为3/24(12.5%),UAE组为7/27(25.9%)。
- 24个月内研究组无患者需要再干预,对照HIFU组为15/24(62.5%)。
临床应用与阅片要点
- 作者认为该治疗可能带来优于UAE的长期影像和临床结果,但需更大规模随机对照试验进一步评估。
局限性
- 研究组仅9例连续患者,样本量小。
- 作者指出需要更大规模的随机对照试验来进一步评估该治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The use of a modified energy transmission protocol and oxytocin augmentation is being proposed as a high-intensity-focused ultrasound (HIFU) treatment for uterine fibroids, to aim for an effective and well-tolerable treatment to be given as an out-patient procedure without anesthesia or sedation. The objective of this study was to evaluate the safety and treatment effectiveness of this new protocol. The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27). There was no major adverse event. At 3 mo, the median proportion of fibroid volume compared with the baseline was 51.1% in the study group, significantly smaller than that in the control groups (HIFU 76.6%, UAE 66.2%). At 6 mo, all patients in the study group became symptom free (9/9, 100%), a result significantly better than that of both control groups. The proportion of patients with good quality of life was significantly higher in the study group (5/7, 71.4%) compared with the control groups (HIFU 3/24, 12.5%; UAE 7/27, 25.9%). Within 24 mo, none of the patients in the study HIFU group required re-intervention, a result significantly better than that in the control HIFU group (15/24, 62.5%). The treatment could result in a very promising long-term imaging and clinical outcome that may be better than those of UAE; however, a randomized control trial of larger scale is required for further evaluation of this treatment.
引用
- Yu SC, Cheung EC, Leung VY, et al. Oxytocin-Augmented and Non-Sedating High-Intensity-Focused Ultrasound (HIFU) for Uterine Fibroids Showed Promising Outcome As Compared To HIFU Alone or Uterine Artery Embolization. Ultrasound Med Biol. 2019. PMID: 31493956. doi:10.1016/j.ultrasmedbio.2019.07.410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。